Screening for hyperlipidaemia in diabetics
The article by Paterson et al. ,I which we read with interest, clearly emphasizes the importance of detecting and treating lipid abnormalities in diabetics with good glycaemic control. May we also stress the fact that in metabolic terms diabetes mellitus should be regarded as an insulinopathy affecting carbohydrate, lipid and protein metabolism. However, greater emphasis has been given to the derangement in carbohydrate metabolism since hyperglycaemia is the only criterion by which diabetes mellitus can be diagnosed, and attaining a good glycaernic control (as judged by measuring blood glucose and glycosylated haemoglobin) is the current accepted index of successful therapy.l Ignoring the lipoprotein abnormalities will only predispose the diabetic patient to accelerated atherosclerosis with subsequent increased risk of cerebral, coronary and peripheral vascular disease.
In contrast to the findings of Paterson et al. , it is well established that the most common lipid abnormality associated with diabetes mellitus is hypertriglyceridaemia, a consequence of increased hepatic synthesis of very low density lipoprotein (VLDL).3 The catabolic degradation of this triglyceride-rich particle leads to the formation of intermediate density lipoprotein (IDL), a potentially atherogenic molecule. Therefore, it is reasonable to use dietary measures and a triglyceride lowering medication, e.g. a fibrate derivative in diabetics with hypertriglyceridaemia in order to reduce the risk of development of atherosclerosis." The aim of diabetic treatment should be to attain normoglycaemia and normolipidaemia.
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